Pharsight

Doptelet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7638536 AKARX INC 2-Acylaminothiazole derivative or salt thereof
Jul, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765764 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jan, 2023

(1 year, 4 months ago)

US8338429 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jun, 2023

(11 months ago)

Doptelet is owned by Akarx Inc.

Doptelet contains Avatrombopag Maleate.

Doptelet has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Doptelet are:

  • US8765764
  • US8338429

Doptelet was authorised for market use on 21 May, 2018.

Doptelet is available in tablet;oral dosage forms.

Doptelet can be used as treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure, treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment.

Drug patent challenges can be filed against Doptelet from 21 May, 2022.

The generics of Doptelet are possible to be released after 28 July, 2027.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-246) Jun 26, 2026
New Indication(I-802) Jun 26, 2022
New Chemical Entity Exclusivity(NCE) May 21, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AVATROMBOPAG MALEATE ingredient

NCE-1 date: 21 May, 2022

Market Authorisation Date: 21 May, 2018

Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytop...

Dosage: TABLET;ORAL

More Information on Dosage

DOPTELET family patents

Family Patents